A research study on magic mushrooms in Canada discovered that nearly 80% of the participants are in favor of psilocybin being accessible as a medical treatment for patients in distress. Furthermore, about two-thirds of the Canadian participants in the study concurred that psilocybin should be legal for those who need it.
Beyond just making the substance available, a substantial 84.8 percent of the participants express the belief that the costs of such therapies should be borne by the public health system. A significant number of Canadians view psilocybin as a feasible option, particularly for the treatment of end-of-life distress.
[toc]
Key Findings:
- Residents of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a legitimate medical solution for addressing end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants in two double-blind trials reported immediate and lasting benefits, with effects persisting for six months or more.
Understanding Existential Distress
Existential distress, similar to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Such patients may undergo feelings of helplessness, isolation, anxiety, and a loss of purpose. This distress significantly impacts patients with life-threatening illnesses, potentially leading to a wish for hastened death or thoughts of suicide.
Generally, individuals confronted with terminal illnesses or major life changes are the ones who frequently experience this type of distress. It severely impacts their mental health and overall life quality.
Existential therapy aims to address issues like anxiety, depression, grief, loneliness, apathy, despair, identity confusion, feelings of purposelessness and existential fear. This therapy may require multiple sessions and might not be effective for everyone.
The uncertainty regarding the efficacy of such therapy is a main reason why many seek alternative treatments.
The Stance of Health Canada on Psilocybin as a Therapeutic Alternative
Over the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in treating complex mental disorders. Specifically, psilocybin has demonstrated its capacity to quickly and sustainably ease existential distress in patients who are close to the end of their lives.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments fail, Health Canada revised the Special Access Program in 2022. This revision enables healthcare providers to request controlled substances for their patients.
Canadians’ Endorsement of Psilocybin Access
A study published in the Palliative Care Journal examines public opinions on psilocybin-assisted therapy for end-of-life care. The study’s data includes:
| Methodology | Engagement from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these participants have previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be included in medical treatment. 84.8% endorse the offering of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
The outcomes align with surveys conducted in Canada, England, and Australia. The researchers pointed out that their study is distinctive because it focuses on the use of psychoactive substances to alleviate existential distress in end-of-life situations.
Reasons for Canadian Endorsement of Psilocybin Use
An increasing number of Canadians are welcoming the use of psilocybin for treatment, primarily due to insights from reputable research institutions. Another contributing element is the perceived safety of psilocybin mushrooms in easing existential distress. Participants in various studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and enduring |
| The benefits can last for six months or more. The effectiveness of the therapy is largely due to the mystical experiences that provide a sense of unity and deep emotional insights. | ||
| Trial at New York University | Twenty-nine patients were randomly selected to receive either psilocybin or the active placebo, niacin. | The results were similar to those of the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a better understanding of life and death. |
| BMC Palliative Care | Nineteen participants, which included 7 doctors, 4 nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The aim of the study was to understand the perception of palliative care professionals towards existential distress and their view on psychedelic therapy as a treatment option. | Palliative care practitioners believe that psychedelic-assisted therapy (PAT) has the potential to alleviate existential distress. |
Patient Experiences
Scientific studies are not the only form of evidence supporting the effectiveness of psilocybin. Numerous patient stories highlight its ability to improve mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares an enlightening experience from her assisted therapy. She describes being on a raft, surrounded by nature, and accompanied by whimsical creatures. This vision deepened her understanding of the universe’s interconnectedness and support, providing her with immense peace and affirmation.
Despite receiving conventional mental health support, Yokoi continued to suffer from severe anxiety and distress after her diagnosis. Psilocybin therapy helped her reconnect with her body and provided a tangible sense of love and support. This significantly improved her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare when the study was conducted and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs since her therapy session, she stated that the experiences had brought meaning and reality to her beliefs.
Brenda’s Journey
In the course of her therapy, Brenda experienced the sensation of dying twice. These experiences led to a change in her perception of death, which she began to view as a beautiful aspect of the cycle of life. She recognized the research as the catalyst for her healing journey from childhood trauma. The data collected throughout her journey reflected this profound change. She exhibited decreased anxiety and fear of death, while her spirituality increased significantly.
Availability of Magic Mushroom Products in Canada
At present, the accessibility of psilocybin capsules and other related products designed for handling existential anxiety or other mental health problems might be limited. However, reliable online dispensaries serve as a viable source for obtaining these products when necessary.
| Characteristic | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Sourced from Brazil and some surrounding South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Related to the popular Penis Envy mushrooms from the 1970s. |
| Potency | Moderately potent; appropriate for beginners. | Moderate potency; suitable for those new to the experience. | Highly potent; recommended for individuals with moderate to extensive experience. |
| Effects | Produces a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual encounters, increased creativity, and better focus. | Triggers an energizing and enduring high, minor visual changes, boosted creativity, euphoria, a gentle physical high, fractal visuals, and feelings of joy. | Promotes profound shamanic experiences, vision quests, intense mystical experiences, enhanced creativity, focus, social awareness, and mood improvement. |
Easing End-of-life Discomfort with Psilocybin Products
Existential or end-of-life distress can significantly affect many patients nearing the end of their lives. Conventional treatments for such distress may not always be effective, leading to a surge in Canadian demand for public healthcare to provide easier access to magic mushrooms. This growing public interest could
We urge regulatory authorities to consider the potential of magic mushrooms as a valid therapeutic option. For your psychedelic requirements and mushroom delivery, rely on Buy Shrooms Online Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Psychedelic-assisted therapy (PAT) outcomes can greatly differ among patients. Adhering to certain procedures and adequate preparation are crucial for a positive result. Prior to the intake of the substance, patients must undergo a detailed screening and mental readiness assessment.
- Pre-Session Preparation: Prior to the session, patients go through an extensive assessment. The therapist outlines the patient’s goals and expectations, setting the session’s objectives. The therapist also informs the patient about the potential effects and what they should anticipate during the process.
- The Session: During the session, the patient receives a regulated dose of the substance in a calm, distraction-free environment, promoting relaxation and self-reflection. The therapist offers ongoing assistance and guidance throughout the session.
- Post-Session Integration Therapy: This therapy helps patients comprehend and process their experiences. Follow-up sessions provide ongoing support and counselling to reinforce the insights and transformations gained during the therapeutic process.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by latching on to serotonin receptors, notably the 5-HT2A receptor. This interaction can provoke changes in perception, mood, and cognition, yielding considerable shifts in consciousness, emotional disclosures, and novel perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients suffering from certain mental health disorders or existential distress are carefully screened to exclude those with a history of psychosis.
Related Readings:
